AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05260112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERICA
Description: Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses.
Study NCT06454175 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: immunization schedule：Month 0，Month 2，Month 6
Study NCT06454175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)
Description: immunization schedule：Month 0，Month 2，Month 6
Study NCT06069102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.
Study NCT06069102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tight blood pressure control
Description: The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.
Study NCT04362826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel probiotic
Description: Investigational novel probiotic
Study NCT04362826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for probiotic
Study NCT06301412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C
Study NCT04731376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
Study NCT04731376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Given IM
Study NCT05662241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obexelimab
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
Study NCT05662241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05094921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Halliwick method
Description: The Halliwick Concept is a detailed swimming programme based on the scientific principles of body mechanics and the properties of water intended to educate individuals with special needs to be water safe and to move independently in the water as much as possible (Lambeck \& Stanat 2001a).The programme consists of 10 specific progressive stages that are achieved without the use of floatation devices (Lambeck \& Stanat 2001b).
Study NCT05094921 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional selected exercise program for 60 minutes ,3 session per week for 3 successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises to improve postural control and correct spinal deformities (3) improving postural responses, (4) Flexibility exercises of the soft tissue (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
Study NCT04777721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
Study NCT05463042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.
Study NCT05463042 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Normoxia (sham)
Description: During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
Study NCT05315232 — intervention group
Intervention type: OTHER
Intervention: survey and interview
Description: qualitative assessment
Study NCT05941351 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: flap fixation
Description: flap fixation using running or interrupted sutures
Study NCT04793386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: carotid ultrasound
Description: Every time checking pulse, evaluate the carotid artery compressibility and pulsatility by ultrasound
Study NCT06374212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: 900mg maintenance dose every 4 weeks for 12 weeks then 600mg loading dose every 4 weeks until week 20
Study NCT06376513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation
Description: Evaluation of the manipulation abilities of patients with penile prostheses Evaluation of the rigidity of erections with penile prosthesis, the patient and partner's sexual satisfaction, the satisfaction related to pump manipulation
Study NCT05486260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DMB lowest dose
Description: Intake of 150 mg of DMB
Study NCT05486260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DMB highest dose
Description: Intake of 300 mg of DMB
Study NCT05486260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry lyophilisate
Description: Intake of 300 mg of strawberry lyophilisate
Study NCT05859542 — intervention group
Intervention type: DEVICE
Intervention: Videolaryngoscope first
Description: started the session with 3 intubations using the videolaryngoscope
Study NCT05859542 — intervention group
Intervention type: DEVICE
Intervention: Direct laryngoscope first
Description: started the session with 3 intubations using the Direct laryngoscope
Study NCT05865314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimisation of nutrition therapy coupled with early mobilisation
Description: Optimisation of nutrition therapy coupled with early mobilisation with:~* Optimisation of nutrition therapy during ICU stay~* Optimisation of physiotherapy during ICU stay~* Better communication and closer collaboration between physiotherapy and nutrition teams.~* Optimisation of continuity of the care.
Study NCT05865314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients will receive nutritional therapy and mobilisation according to local standard procedures.
Study NCT06316882 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening endoscopy
Description: We perform upper endoscopy, when the patient authorizes it, during their screening colonoscopy
Study NCT06552104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACUPRESSURE APPLI ACUPRESSURE APPLICATION
Description: Pre-test data were collected from participants who met the inclusion criteria and volunteered to participate in the study by researcher BI in the LDP rooms during the latency period of labor. Post-test data were obtained by the same researcher 16 hours after the cesarean section. Data were obtained using the Personal Information Form, Episiotomy Evaluation Form (EEF), Visual Analog Scale (VAS), and Spielberger Manual for State-Trait Anxiety Inventory (STAI).
Study NCT05606679 — intervention group
Intervention type: GENETIC
Intervention: Analysis combinations of maternal KIR and HLA-C genotypes
Description: Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients
Study NCT04837534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling group
Description: In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
Study NCT04837534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS and phone call reminder group
Description: In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
Study NCT04389580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Isotretinoin plus Tamoxifen
Description: 20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen
Study NCT04389580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized Isotretinoin plus Tamoxifen
Description: 20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen
Study NCT04996264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib Methyl
Description: Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.
Study NCT04996264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.
Study NCT04996264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care (SOC)
Description: SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
Study NCT04996264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC)
Description: SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
Study NCT05245825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
Study NCT06197932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine exercise and running training
Description: impact of a 4-week running training program on physical performance variables in a control group comprising 15 participants. The control group exclusively underwent running training, and measurements were taken for variables such as the strength of the big toe of both right and left feet using a hip and toe dynamometer (measured in kilograms). Additionally, assessments included vertical jump height and horizontal jump distance (both measured in centimeters), balance using the Y-balance test, and agility via the T-test. All measurements were conducted with standardized equipment, both before and after the training period. se physical performance indicators.
Study NCT06197932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big Toe Strengthening Exercise
Description: impact of a 4-week intervention involving toe-strengthening exercises and concurrent running training on 15 participants. Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for three weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
Study NCT05245825 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary plan
Description: Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
Study NCT05018325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with 6 minute withdrawal
Description: Withdrawal time will be determined using a digital stopwatch by the nursing staff.
Study NCT05018325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy 9 minute withdrawal
Description: Withdrawal time will be determined using a digital stopwatch by the nursing staff.
Study NCT05018325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy 12 minute withdrawal
Description: Withdrawal time will be determined using a digital stopwatch by the nursing staff.
Study NCT04581317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.
Study NCT05601544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day
Description: Sphere CONTROL
Study NCT04581317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AES 8 basic usage
Description: For the second 6 weeks, participants will continue to have meal deliveries and will now have the AES 8 device which can be used by the cognitively impaired participant and their caregiver. AES 8 devices will be installed in participant's homes by the study team and participants will be given basic instructions on using the device as well as a one-page handout that will include instructions on how to use and maintain privacy with their device. The study staff will continue to call twice a week to ask the 5 questions. At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
Study NCT04581317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AES 8 advanced usage
Description: In the third 6 weeks, the participants will continue to have meal deliveries and the AES 8 will be upgraded to provide an active intervention by asking the twice a week 5 questions through the device. The questions should be answered by the cognitively impaired older adult using the device, though the caregiver can still use the device for other basic services. The participant will be able to answer the questions verbally or by touch screen options displayed on the device.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
Study NCT05364190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
Study NCT06403683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: WaLIDD score / Insomnia Severity Index (ISI) / International Physical Activity Questionnaire (Short-form) / Six-Minute Walk Test
Description: Case control trial study
Study NCT05414084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral (poly)phenol challenge test (OPCT)
Description: Nutritional challenge with standardized (poly)phenol-rich tablets
Study NCT06110247 — intervention group
Intervention type: DEVICE
Intervention: NIRS
Description: After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.
Study NCT06110247 — intervention group
Intervention type: OTHER
Intervention: Taking a blood sample
Description: Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
Study NCT04953078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baiya SARS-CoV-2 Vax 1
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
Study NCT05601544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS MAX 1-Day
Description: Sphere TEST
Study NCT05601544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS Multifocal
Description: Multifocal CONTROL
Study NCT05601544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS MAX 1-Day Multifocal
Description: Multifocal TEST
Study NCT05601544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism
Description: Toric CONTROL
Study NCT05601544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A based contact lens (toric) with new UV/HEV filter
Description: Toric TEST
Study NCT04612348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Point of care ultrasound to measure gastric contents.
Study NCT05102409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed once
Study NCT05102409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiidra® (5% lifitegrast ophthalmic solution)
Description: Xiidra® (5% lifitegrast ophthalmic solution) dosed once
Study NCT06397963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT307 injection
Description: GT307 injection to treat solid tumours
Study NCT04920890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency therapy with manual therapy
Description: Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
Study NCT05364190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
Study NCT04977193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY011
Description: CAR-T
Study NCT05209425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
Study NCT06167239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques
Description: New techniques to train inspiratory muscles in mechanically ventilated patients
Study NCT05020782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: INTERVENTION DRUG: BELIMUMAB 10 MG/KG
Study NCT06282510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone Iodine Topical
Description: Topical intranasal povidone iodine (10%) twice daily for 5 days
Study NCT05036135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation